A phase 2a double-blind, placebo-controlled randomized clinical trial to evaluate immunogenicity & safety of a Zika virus vaccine (Bbv121) in Dengue sero-negative & dengue sero-negative & Dengue sero-positive healthy adults | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

A phase 2a double-blind, placebo-controlled randomized clinical trial to evaluate immunogenicity & safety of a Zika virus vaccine (Bbv121) in Dengue sero-negative & dengue sero-negative & Dengue sero-positive healthy adults

Implementing Organization

All India Institute of Medical Sciences

Principal Investigator

Mr. M.V. Murhekar Director All India Institute of Medical Sciences Delhi

Related Research

Quick Information

Area of Research

Medical Sciences

Focus Area

Task Force (TF)

Start Year

2020

End Year

2021

Duration

24

Sanction Amount

₹ 5.57 Cr

Status

Completed

Output

No. of Research Paper

00

Technologies (If Any)

00

No. of PhD Produced

00

No. of Patents

Filed : 00

Grant : 00

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Latest Updates

Loading…